Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132052 · ClinicalTrials.gov registry record
Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 81
- Enrollment target
NCT02132052: Completed study, sponsored by University of Colorado, Denver.
NCT02132052 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02132052 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
Investigators hypothesize that there are specific characteristic of each cognitive and motor condition that can be defined using brains scans.
Primary Outcome
Focal oscillatory activity: Focal band power for delta (0.5-4Hz), theta (4-8 Hz), alpha (9- 13 Hz), low beta (13-20 Hz), high beta (20-30 Hz) and gamma (30-50 Hz) activity will be derived from the autoregressive models.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-05 |
What the finished NCT02132052 record still lists
NCT02132052 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02132052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02132052 about?
NCT02132052 is a clinical study titled "Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.". Investigators hypothesize that there are specific characteristic of each cognitive and motor condition that can be defined using brains scans.
What is the current status of trial NCT02132052?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2013-11. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT02132052?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia